Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to ...

A study conducted at the Federal University of São Paulo (UNIFESP) in Brazil has concluded that the use of monochromatic ...

The study was conducted at the Federal University of São Paulo and involved 144 diabetic patients, who were treated with ...

Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect for patients undergoing cancer treatments, and ...

If you’re suffering from stabbing pain, numbness, tingling or a burning sensation in your arms, legs, hands or feet, you may ...

Dr. Jeff Watson, with Dynamic Spine and Neuropathy in Sioux Falls, is a leading expert in the field of chiropractics. He recently released a groundbreaking new book titled “A Patient’s ...

Averitas Pharma, the US subsidiary of Grünenthal, has completed patient recruitment for the Phase III AV001 clinical study, ...

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will present new data on minimal residual disease (MRD) negativity rates from the Phase 3 CARTITUDE-4 trial ...

Data from the SENZA-PDN trial showed 10 kHz SCS yielded long-term, clinically meaningful reductions in HbA1c and weight in patients with PDN and T2D.

“Patients sometimes tell me that they ‘hear bad things’ about [ED treatments],” Dr. Gross told The Post. “These medications are among the most broadly prescribed drugs of the last ...